Finvest
MASI Medical Technology · Medtech · Merger arbitrage · Patient monitoring · Thesis updated June 14, 2026

Masimo became a deal-closing story

01 Running thesis

The deal now drives the stock

Masimo is no longer mainly a debate about hospital monitors, margins, or sensor growth. The internal thesis now treats it as a merger-arbitrage stock. That means the key question is simple: does the Danaher cash deal close at the agreed price?

The bull case is that Danaher pays Masimo holders $180.00 per share. Masimo stockholders approved the merger agreement on May 1, 2026, which removed one of the biggest ways the deal could fail. After that vote, the main internal hurdle left was regulatory approval.

The bear case is that the deal fails, most likely because regulators block it or require terms that break the agreement. If that happened, the stock would likely trade on Masimo's standalone business again. That could mean a much lower price than the deal value.

There is one important timing tension. Public reports from Danaher say the acquisition was completed on June 10, 2026. The internal thesis file still frames Masimo as pending deal risk after the May 1 stockholder vote, so this page treats the latest internal view as the base case while flagging deal completion status as the main item to verify.

May 2026▲Masimo disclosed that stockholders approved the Danaher merger agreement on May 1, 2026. That removed a major deal hurdle and left regulatory approval as the main internal risk.
May 2026→The 10-K/A added Part III information and did not change the business, risk, or merger thesis.
Feb 2026▲Masimo announced a definitive cash merger agreement with Danaher at $180.00 per share. The thesis shifted from standalone execution to deal completion.
Nov 2025▲Q3 2025 results showed 8.2% revenue growth in the filing and better margins. The Sound United sale was complete, but distributor concentration became a clearer risk.
Aug 2025▲The Q2 2025 filing said manufacturing had returned to normal after the cybersecurity incident. It also quantified the net cost at $4.5 million and added tariff and Medicaid funding risks.
May 2025→Masimo agreed to sell its non-healthcare business for $350 million, supporting the pure-play Healthcare plan. A cybersecurity incident added near-term operating risk.
02 Business model

Hospitals buy the platform, then sensors

Masimo sells noninvasive monitoring technology to hospitals and care settings. Noninvasive means doctors can track signals from the body without cutting into the patient or taking repeated blood samples.

The attractive part of the model is the installed base. Once a hospital adopts Masimo's monitors, it often needs sensors and other consumables over time. That can make revenue more repeatable than a one-time equipment sale.

Masimo also spent 2025 cleaning up its structure. The former Sound United consumer business was moved into discontinued operations, and Masimo completed the sale of Sound United on September 23, 2025. The company is now treated as a pure-play Healthcare business in the internal view.

The model can break if hospitals slow purchases, if a key distributor changes behavior, or if deal uncertainty distracts customers and employees. For fiscal 2025, one just-in-time distributor represented 18.8% of total revenue, which is high concentration for a company tied to hospital supply chains.

03 Product portfolio

Monitoring is the core

Cash cow

Noninvasive monitoring systems

These are the core hospital systems Masimo is known for. They help clinicians track patient signals without invasive tests.

Growth engine

Sensors and consumables

Sensors and related consumables are the recurring part of the model. More hospitals using Masimo platforms can lead to more follow-on sensor demand.

Option

AI-enabled monitoring

Masimo is investing in smarter monitoring tools that help hospitals watch patients more closely. This is a growth option, but the merger story is currently more important for investors.

Option

Wearables and connected care

Management has pointed to wearables as one future growth wave. The value depends on adoption outside Masimo's traditional hospital base.

Steady

Former Sound United products

This was the consumer audio and non-healthcare business. It was classified as discontinued operations and sold in 2025, so it is no longer the main Masimo story.

04 Business segments

One continuing segment

Healthcare continuing operations100%modest
Discontinued non-healthcare operations0%declining

Masimo reports Healthcare as its continuing operating segment after the Sound United divestiture. The fiscal 2025 caveat is concentration: one just-in-time distributor represented 18.8% of total revenue.

05 Risk factors

What could still go wrong

Deal status mismatch

High impact · Medium odds

The internal thesis still centers on a pending Danaher acquisition after the May 1, 2026 stockholder vote. Public Danaher materials say the acquisition was completed on June 10, 2026. Investors should verify the current trading, payout, and delisting status before treating MASI like a normal public stock.

We watchCheck Danaher and Masimo press releases, Nasdaq trading status, and broker corporate action notices.

Regulatory approval failure

High impact · Low odds

Before completion, the main remaining deal risk was regulatory approval in the United States and other countries. If regulators blocked the deal or demanded major remedies, the $180.00 cash outcome could fail. The stock would then likely trade on standalone earnings and growth.

We watchLook for HSR Act updates, international antitrust decisions, and any revised closing language from Danaher or Masimo.

Break-price risk

High impact · Medium odds

Merger-arbitrage stocks can fall sharply if a cash deal breaks. Masimo's underlying business grew in fiscal 2025, but the deal price may be above what public markets would pay for the standalone company. That gap is the risk investors are being paid to take.

We watchTrack the spread between MASI's market price and the $180.00 deal price, if the stock is still trading.

Distributor concentration

Medium impact · Medium odds

Masimo depends on a major just-in-time distributor that represented 18.8% of fiscal 2025 revenue. If that distributor changes ownership, terms, ordering patterns, or inventory behavior, Masimo's revenue timing could move quickly. This matters even more during a deal process, when customers may wait for clarity.

We watchWatch future filings for 10% customer disclosures and any comments on distributor ordering.

DOJ investigation overhang

Medium impact · Medium odds

The internal risk file says the DOJ investigation remains ongoing. It is now secondary to merger completion risk, but it has not disappeared. Any settlement, charge, or new disclosure could still affect the business or deal optics.

We watchWatch 10-Q and 10-K legal proceedings sections for changes in DOJ language.
06 Quick answers

In one breath

What does Masimo do?

Masimo makes medical monitoring technology used in hospitals and care settings. Its products help clinicians track patient signals in a noninvasive way, and the company also sells sensors and consumables used with those systems.

Why is the Danaher deal so important for MASI?

Danaher agreed to buy Masimo for $180.00 per share in cash. That made the stock less about normal business growth and more about whether the deal closes and pays that price.

Did Masimo stockholders approve the Danaher merger?

Yes. Masimo said in its Q1 2026 Form 10-Q that stockholders adopted the merger agreement at a special meeting on May 1, 2026. That removed a major uncertainty from the internal merger-arbitrage thesis.

What is the biggest standalone business risk?

Customer concentration is a key risk. For the fiscal year ended January 3, 2026, one just-in-time distributor represented 18.8% of total revenue.